8-K filing — Protagenic Therapeutics, Inc.\new (PTIX)
Filed: 2026-08-20 AccNo: 0001493152-26-039410 Size: 292 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Protagenic Therapeutics Says FDA Raised No Objection To Planned Phase 1 Program Design For PT00114 In Generalized Anxiety Disorder; IND Submission On Track For Q4, First Patient Dosing Targeted For H1 2027
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 20, 2026, 12:34 PM
- Checked
- Aug 20, 2026, 12:34 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading